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Abstract
Objective: To evaluate the feasibility of a large immediate versus deferred antiretroviral therapy (ART) study in
children.
Methods: We conducted an open-label pilot randomized clinical trial study in 43 Thai children with CD4 15 to
24% of starting generic AZT/3TC/NVP immediately (Arm 1) or deferring until CD4 < 15% or CDC C (Arm 2).
Primary endpoints were recruitment rate, adherence to randomized treatment and retention in trial. Secondary
endpoints were % with CDC C or CD4 < 15%. Children were in the trial until the last child reached 108 weeks.
Intention to treat and on treatment analyses were performed.
Results: Recruitment took 15 months. Twenty-six of 69 (37.7%) were not eligible due mainly to low CD4%.
Twenty four and 19 were randomized to arms 1 and 2 respectively. All accepted the randomized arm; however,
3 in arm 1 stopped ART and 1 in arm 2 refused to start ART. Ten/19 (53%) in arm 2 started ART. At baseline,
median age was 4.8 yrs, CDC A:B were 36:7, median CD4 was 19% and viral load was 4.8 log. All in arm 1 and
17/19 in arm 2 completed the study (median of 134 weeks). No one had AIDS or death. Four in immediate arm
had tuberculosis. Once started on ART, deferred arm children achieved similar CD4 and viral load response as
the immediate arm. Adverse events were similar between arms. The deferred arm had a 26% ART saving.
Conclusion: Almost 40% of children were not eligible due mainly to low CD4% but adherence to randomized
treatment and retention in trial were excellent. A larger study to evaluate when to start ART is feasible.
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Background
The Children with HIV Early Antiretroviral Therapy
(CHER) study recently found that more infants rand-
omized to deferring antiretroviral therapy (ART) until
their CD4 fell below 25% died compared to those who
started ART before the age of three months [1] but there is
currently no randomized trial to guide when to start ART
in children older than one year of age. Although, ART has
significantly reduced HIV-related morbidity and mortal-
ity, it is associated with side effects, interference with daily
activities and resistance [2-6]. Deferring the start of ART
could possibly reduce these problems but the risk of HIV
disease progression may increase. This randomized pilot
study was conducted to explore the feasibility and HIV
disease outcome of the immediate versus deferred ART
strategy as a ground work for a larger study.
Recommendations of when to initiate ART differ between
guidelines based on expert advice, published data of out-
come in ART-untreated children and local resources [7,8].
Regular CD4 monitoring allows for opportunity to start
ART prior to clinical progression as CD4 is the most
important determinant for both short and long term HIV
disease progression and death risks [7-9]. All guidelines
recommend ART in children with severe HIV-related clin-
ical events. Infants have a more rapid HIV disease progres-
sion, in fact, the efficacy and safety of immediate versus
deferred ART strategy in older children is not known. Cur-
rently, in children age one year and up, the World Health
Organization (WHO) guidelines for resource-limited
countries and the Thai Ministry of Public Health guide-
lines recommend starting ART when CD4 is in the severe
immune deficiency range according to age groups: 12–59
months (< 20%) and = > 5 years (< 15% or < 200 cells/
mm3) [10-12]. The United States Guidelines recommend
to start ART when CD4 is < 25% [13] while the Pediatric
European Network for Treatment of AIDS recommend
starting ART at CD4 < 20% in children ages 1 to 3 years
and CD4 < 15% in older children [14].
We planned to enroll 43 children within one year and
expected that many children would not be eligible as CD4
monitoring was not performed routinely and many chil-
dren would have lower than required CD4. We also
expected that more children would decline immediate
ART as the Thai guidelines at that time recommended
starting ART when CD4 was below 15%. Regarding the
safety of the two treatment arms, we hypothesized that
with close follow up and CD4 monitoring, ART can be
deferred until CD4 < 15% in children ages 1 to 12 years
old with Center for Disease Control and Prevention
(CDC) clinical class A or B and CD4 15–24% without
affecting HIV disease progression.
Results
Enrollment and retention rates
Between December 2001 and March 2003, 69 children
were screened and 43 were enrolled at two sites (Figure 1).
The recruitment began at the Bangkok site in December
2001, and in October 2002, the Khon Kaen site was
included to increase recruitment. The overall recruitment
rate was 4 children/month. The recruitment was more
rapid towards the end of the study due to the inclusion of
two sites. Twenty six (37.7%) failed screening due to the
following reasons: 24 (92.3%) from CD4 < 15% and 2
(7.7%) from CD4 > 24% The children who were not eligi-
ble had a median age of 6.2 years (IQR 3.7 to 9.7) and
median CD4 of 6.5% (IQR 3.3 – 10.8). All children
accepted the randomized arm; however, three in the
immediate arm stopped ART (one due to family's prefer-
ence after the child had a mild nevirapine rash and two
due to physician's recommendation after ART adherence
cannot be ensured), and one deferred arm child was lost
to follow up after the parents refused for the child to begin
ART when the CD4 fell below 15%. Another deferred arm
child was lost to follow up for unknown reason. The study
ended when the last child reached week 108 of follow up
with a median follow up time of 134 weeks, IQR 123 to
154, all in the immediate arm and 17 of 19 in the deferred
arm completed the study. The median time spent on ART
was 124 weeks (IQR 112–134) in the immediate arm chil-
dren and 99 weeks (IQR 85–107) in the deferred arm chil-
dren who initiated ART.
Baseline characteristics
For the children who were enrolled, baseline characteris-
tics are shown in Table 1. Forty-three children were rand-
omized to immediate (n = 24) and deferred ART (n = 19).
Overall, the median age was 4.8 years (IQR 2.7–6.6) with
17 males and 26 females. Most (84%) had CDC A clinical
disease with a median CD4 of 19% (IQR 17–22) and CD4
count of 615 (541–824), and median viral load of 4.8
log10 copies/ml (IQR 4.3–5.3). Ninety and 77% of chil-
dren had weight and height respectively in the normal
ranges according to growth charts for Thai children (-1.5
to +2 standard deviation).
Initiation of ART in the deferred arm
Ten of 19 (53%) of deferred arm children started ART at a
median time of 29 weeks (IQR 20 – 79), and a median
CD4% and count of 12% (IQR 11–13, range 6 to 14) and
274 cells/mm3 (IQR 220 to 394, range 137 to 555). The
lowest CD4 drop to 6% (137 cells/mm3) was seen in a 31-
month-old child at week 12 who had a baseline CD4 of
18% (571 cells/mm3). She did not have HIV disease pro-
gression and her CD4 rose after ART to 9% (402 cells/
mm3) and 15% (505 cells/mm3) at weeks 24 and 36
respectively. Reason for ART initiation in the deferred arm
was CD4 drop below 15% (n = 5) and CD4 drop by 25%AIDS Research and Therapy 2008, 5:24 http://www.aidsrestherapy.com/content/5/1/24
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Study design and patient disposition Figure 1
Study design and patient disposition. Footnote: All children in the deferred arm started ART because of protocol-defined 
CD4 criteria. All patients reached week 108. Some patients had additional follow up between weeks 120 to 168. Number of 
patients at last follow up visit in immediate/deferred arms = 21/15 at week 120, 13/11 at week 132, 8/5 week 144 and 7/4 at 
week 168). ART: antiretroviral therapy.
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(n = 5), and no difference in outcome was seen between
these children.
Clinical outcome
At the end of the study, no child had AIDS-defining illness
or death. Four immediate arm children had new clinically
diagnosed acid fast bacilli smear-negative pulmonary
tuberculosis (TB) at a median time of 60 weeks (range 48
to 72), and a median CD4 of 28% (IQR 22 – 37) and 637
cells/mm3 (IQR 568 – 894). They responded well to
standard anti-TB treatment. The TB occurrence was not
deemed related to immune reconstitution syndrome due
to the large time gap between ART initiation and TB diag-
nosis and the high TB prevalence in the area. Weight for
age Z score (WAZ) and height for age Z score (HAZ) were
similar between arms.
Immunological outcome
Overall the immediate arm had a higher CD4% and CD4
count compared to the deferred arm (Table 2). At the end
of the study, by ITT, no immediate arm child had CD4 <
15% and 3 children in the deferred arm had CD4 < 15%,
all of whom had < 4 weeks of ART. In Figure 2, the CD4%
in the immediate arm was higher than the deferred arm
children who did not start ART (31%, IQR 24–39 versus
28.5%, IQR 12.8–34.8, p = 0.012). In deferred arm chil-
dren who started ART, the median CD4% was 29%, IQR
13–35 and this was not statistically different than that of
the immediate arm, p = 0.322.
Virological outcome
Overall the immediate arm had a lower viral load than the
deferred arm (Table 2). By ITT, at the end of the study, the
immediate arm had a lower median viral load of 1.7 log10
copies/ml (IQR 1.7 – 2.5) compared to the deferred arm
children who did not start ART (median viral load 1.7
log10 copies/ml, IQR 1.7–4.8), p = 0.024 (Figure 3). How-
ever, once the deferred arm children initiated ART, their
viral load was similar to the immediate arm (median viral
load 1.7 log10 copies/ml, IQR 1.7 – 1.7), p = 0.580. The
proportion of children with viral load < 400 and < 50 cop-
ies/ml were 75% (18 of 24) and 67% (16 of 24) in the
immediate arm and 70% (7 of 10) and 60% (6 of 10) in
the deferred arm children who initiated ART respectively,
p = 1.000 and 0.714 respectively.
Cost and toxicities
The deferred arm had 26% less time on ART with 31
months (IQR 28.1 – 33.4) and 25 months (IQR 21.2 –
26.7) of ART in the immediate and deferred arms respec-
Table 1: Baseline characteristics
Characteristics Study arms
Arm 1: Immediate
(n = 24)
Arm2: Deferred
(n = 19)
Gender [M : F], n (%) 10: 14 (42 : 58) 7: 12 (37 : 63)
Median age, years (IQR) 5.2 (2.4 – 8.0) 4.4 (2.7 – 5.8)
Age group, n (%)
❍ 1 – 4 yrs 12 (50) 10 (53)
❍ 5 – 12 yrs 12 (50) 9 (47)
Median weight for age z-scores (WAZ) (IQR) -1.0 (-1.5 to 0.4) -0.1 (-1.5 to 0.3)
Median height for age z-scores (WAZ) (IQR) -1.7 (-2.0 to -0.9) -0.8 (-1.7 to 0.1)
HIV transmission, n (%)
❍ Blood product or transfusion recipient 2 (8) 0
❍ Mother to child transmission 21 (88) 19 (100)
❍ Unclear 1 (4)* 0
Exposed to AZT as prophylaxis against vertical HIV transmission, n (%)** 5/13 (39) 4/11 (37)
CDC categories, n (%)
❍ A 20 (83) 16 (84)
❍ B 4 (17) 3 (16)
Median percent CD4+ count, % (IQR) 19 (16 – 22) 20 (17 – 22)
Median CD4+ count, cells/mm3 (IQR) 649 (509 – 834) 615 (544 – 818)
Median plasma viral load, log10 copies/ml (IQR) 4.8 (4.3 – 5.3) 4.8 (4.1 – 5.1)
Median hemoglobin, g/dl (IQR) 10.8 (10.2 – 11.7) 11.2 (10.6 – 11.8)
Median alanine transferase, IU/L (IQR) 20 (11 – 30) 17 (15 – 23)
Median glucose (mg/dL) at week 48 83 (74 – 90) 81.5 (70.5 – 88)
Median cholesterol (mg/dL) at week 48 173 (153 – 195) 165 (150 – 186)
Median triglyceride (mg/dL) at week 48 69 (54 – 88) 98 (70 – 148)
*This child had no blood transfusion and his parents were not HIV-infected
**Information available in 24 patients
Note: all characters and baseline data did not differ between the two arms except median triglyceride was higher in the deferred arm (p 0.016).AIDS Research and Therapy 2008, 5:24 http://www.aidsrestherapy.com/content/5/1/24
Page 5 of 9
(page number not for citation purposes)
Intention to Treat analysis of CD4% in the immediate arm, deferred arm without ART initiation and deferred arm with ART  initiation Figure 2
Intention to Treat analysis of CD4% in the immediate arm, deferred arm without ART initiation and deferred 
arm with ART initiation. * P-value represents difference within the three groups by by Kruskal Willis test.
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Table 2: Outcomes at end of study (median time of 134 weeks)
Data Immediate
n = 24
Defer
n = 19
P
HIV-related illness
No. patient (%) 4 (16.7) - 0.118
Adverse events
No. patient (%) 22 (91.7) 19 (100) 0.495
No. event (% per month) 100 (13.3) 97 (17.0) 0.081
ARV-related adverse events
No. patient (%) 7 (29.2) 4 (21.1) 0.728
No. event (% per month) 10 (1.3) 5 (0.7) 0.467
Median weight for age Z-scores (IQR) -1.1 (-1.5 to -0.8) -1.0 (-1.7 to 0.2) 0.525
Median height for age Z-scores (IQR) -1.4 (-2.0 to -0.8) -0.8 (-1.3 to -0.4) 0.171
Median CD4% (IQR) 31 (24 – 39) 23 (17 – 31) 0.032
Median CD4% change (IQR) 13.5 (4 – 18) 3 (-2 to 13) 0.012
Median viral load*, log (IQR) 1.7 (1.7 – 2.5) 3.1 (1.7 – 4.5) 0.039
Median change viral load, log (IQR) -2.8 (-3.4 to -1.9) -1.8 (-3.2 to -0.3) 0.079
Median Hemoglobin, g/dL (IQR) 11.7 (10.9 – 12.5) 11.7 (10.9 – 12.5) 0.961
Median alanine transferase, unit/mL (IQR) 15 (12.3 – 21.8) 18 (14 – 23) 0.418
Median triglyceride, mg/dL (IQR) 72 (46 – 109) 98 (61 – 156) 0.106
Median cholesterol, mg/dL (IQR) 158 (152 – 202) 160 (143 – 180) 0.197
Median glucose, mg/dL (IQR) 77 (67 – 87) 76.5 (72.3 – 90.5) 0.833
*Median viral load in the 10 deferred arm children who started ART was 1.7 log (IQR 1.7–1.7) which was similar to that in the immediate arm 
children (p = 0.58)AIDS Research and Therapy 2008, 5:24 http://www.aidsrestherapy.com/content/5/1/24
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tively, p = 0.012. Median difference of time on ART
between the two arms was 6.2 months (95% CI 3.3 – 9.9)
Both adverse events related and not related to ART
occurred at a similar frequency between arms (Table 2).
Anemia due to zidovudine (3 of 15 events) and rash due
to nevirapine (3 of 15 events) accounted for most ART-
related adverse events. One child switched from zidovu-
dine to stavudine for anemia and 3 switched from nevi-
rapine to efavirenz for rash. There were no differences
between arms for hemoglobin, ALT, and fasting glucose,
cholesterol and triglyceride (Table 2).
Discussion
Our study showed that recruitment of ART-naïve children
ages 1–12 years with CDC A or B and CD4 15–24% for a
randomized trial of immediate versus deferred ART was
feasible although the recruitment took longer than antici-
pated due to almost 40% of children being ineligible
mainly from low CD4%. The randomized treatment was
accepted in all families. Adherence to randomized treat-
ment and retention rate in trial were high. No child had
AIDS-defining illness or death. Four children in the
immediate arm had clinically diagnosed pulmonary TB.
Half of the deferred arm children started ART because of
protocol-defined CD4 decline. For those who were on
ART, the CD4 and viral load responses, and ART-related
adverse events were similar regardless of treatment arms.
The deferred arm had 26% less time on ART.
The risk for HIV disease progression rises with lower
CD4%, higher viral load and younger age [7]. In earlier
studies when no therapy or only zidovudine mono-
therapy was used, CD4 < 15% significantly increased the
risk of AIDS and death [15-17]. Only one-third of
untreated Thai children were alive without AIDS at 6 years
of age [16]. Immediate versus deferred zidovudine mono-
therapy in children and adults have shown no difference
in AIDS-free survival [18-21] but such randomized study
in children older than one year of age using combination
ART has not been done.
Our study was conducted when the government program
providing free ART and monitoring was not available and
the Thai Ministry of Public Health guidelines recom-
mended ART initiation when CD4 was below 15%. Not
surprisingly, almost 40% were ineligible from low CD4%
since the majority of children had never had CD4 moni-
toring prior to the screening visit. The number of ineligi-
ble children can be reduced in subsequent studies if CD4
can be measured prior to screening as part of routine care.
Improving recruitment rate by enrolling at multiple sites
is important. We anticipated that some families of chil-
dren randomized to immediate therapy would refuse the
Intention to Treat analysis of viral load in the immediate arm, deferred arm without ART initiation and deferred arm with ART  initiation Figure 3
Intention to Treat analysis of viral load in the immediate arm, deferred arm without ART initiation and 
deferred arm with ART initiation. * P-value represents difference within the three groups by by Kruskal Willis test.
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randomized arm, however, none did. The ample time
spent during the consenting process likely alleviated par-
ents' concerns about early therapy. One family in each
arm subsequently refused the randomized treatment. This
illustrates the importance of continued education about
the study through out the trial.
None of the children had HIV disease progression despite
the deferred arm children having lower CD4. This was
likely due to the safety measures of frequent CD4 moni-
toring, immediate cotrimoxazole prophylaxis for Pneumo-
cystis jerovecii pneumonia after the first CD4 < 15% and
ART initiation shortly thereafter if repeated CD4 was con-
firmed to be low. Such safety measures are important
when deferred ART is evaluated. It was not unexpected to
find 4 children, all in the immediate arm, with pulmonary
TB as Thailand is a high TB prevalence area.
The CD4 recovery and viral load suppression were similar
in both arms despite the deferred arm having lower CD4
at ART initiation. Low baseline CD4 had been shown to
dampen such responses [2,22,23]. We did not see more
nevirapine hypersensitivity in the immediate arm despite
higher CD4 being one of its risk factors [24]. The median
difference of time on ART between the two arms in this
small study was not large (6.2 months). Whether ART sav-
ings with deferred treatment will have a high impact in
lowering cost burden for resource-limited countries, it
needs to be evaluated in a larger study.
The main limitation for our study is the small sample size.
We do not have the statistical power to show the differ-
ences in clinical efficacy and safety between the two treat-
ment strategies. This sample size was; however, adequate
for the purpose of evaluating feasibility of this strategy.
The ART savings could be overridden by the costs for addi-
tional CD4 testing and monitoring visits which we were
unable to quantify. We did not assess other important
aspects that could affect the decision to start ART earlier or
later such as neurocognitive function, vaccine response,
quality of life and adherence to ART.
We learned from this pilot study about the feasibility and
design of a more definitive randomized study addressing
the question of when to start ART in children one year of
age or older. Pre-screening CD4 as part of routine care,
giving ample time for consenting, continuing education
about the study through out the trial and including chil-
dren at multiple sites are important for recruitment and
adherence to treatment arms. The length of follow up and
the sample size should be increased. With treatment
becoming more effective and easier to take, the rates of
AIDS and death may be low in both early and deferred
ART; therefore, it is important to include minor HIV-
related illnesses, non-HIV-related illnesses, growth, neu-
rocognition and quality of life as outcomes.
Conclusion
Our study suggests that it is feasible to evaluate the imme-
diate versus deferred ART strategy in a larger study but
many children were not eligible due to low CD4%. The
adherence to randomized treatment and retention rate in
trial were high. The strategy of deferred treatment
appeared to be safe.
In fact, using the lessons learned from this pilot study, The
PREDICT study (Pediatric Randomized to Early versus
Deferred Antiretroviral Initiation in Cambodia and Thai-
land) conducted by our group has completed enrollment
of 300 children in Thailand and in Cambodia. Results are
expected in 2011.
Methods
This open-label pilot randomized clinical trial was con-
ducted between December 2001 and March 2005, Thai
children with HIV at two sites in Thailand: The HIV Neth-
erlands Australia Thailand Research Collaboration/Chu-
lalongkorn University in Bangkok and Khon Kaen
University in Northeast Thailand were recruited. After car-
egivers understood and signed informed consent form,
children were screened for CD4% if they were 1–12 years
old, had CDC clinical stage A or B and had never received
ART other than zidovudine as part of PMTCT. The study
was approved by the institutional review boards at Chu-
lalongkorn and Khon Kaen Universities. All caregivers
gave informed consent.
Based on published rates of CD4 rise, anticipation of
excellent adherence and available funds [22], we enrolled
43 children in order to detect a difference in the propor-
tion of children with CD4 < 15% at week 108 of 0% in the
immediate arm and 30% in the deferred arm with 80 per-
cent power (two-sided significance level of 5%) and 5%
lost to follow up rate.
We based our study on the US guidelines HIV disease cat-
egorization [13], which HIV symptoms are categorized as
none (CDC N), mild (CDC A), moderate (CDC B) and
severe (CDC C) while the immunological status is catego-
rized as normal (CD4 = > 25%), moderate immune sup-
pression (CD4 15–24%) and severe immune suppression
(CD4 < 15%)
At the time of this study, we did not include children
younger than 1 year and those with CDC C or with CD4 <
15% as they would be at high risk of AIDS/death if rand-
omized to deferring ART. We did not select children with-
out symptoms or have normal CD4 as it was against theAIDS Research and Therapy 2008, 5:24 http://www.aidsrestherapy.com/content/5/1/24
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standard practice in Thailand at the time of this study to
start ART in such children.
Patient disposition is shown in Figure 1. The children
were randomized to either starting ART immediately
(immediate arm, n = 24) or deferring ART until CD4 fell
to < 15% in those with baseline CD4 20–24% or CD4
drop by 25% in those with baseline CD4 15–19%
(deferred arm, n = 19). The basis for using CD4 drop by
25% was to avoid having children with CD4 15–19%
starting ART soon after entering the study because of a
minor CD4 drop. The randomization was stratified by age
of 1–4 years old and 5–12 years old. In the deferred arm,
a repeat CD4 was performed immediately if CD4 fell
below ART initiation threshold. Cotrimoxazole was
started immediately with the first CD4 fall below 15%
and was continued for at least 3 months until two consec-
utive CD4 was above 15%. Standard doses according to
the Thai guidelines of generic zidovudine/lamivudine/
nevirapine provided by the Thai Government Pharmaceu-
tical Organization were used. The drugs were given as
individual drugs. All were available in pill and liquid
forms except for nevirapine that was in tablet form only.
A pill cutter was used to give the most accurate dose of
nevirapine. Primary endpoints were 1) recruitment rate 2)
adherence to randomized arm 3) retention in the study.
Secondary endpoints were % children with CDC C or with
CD4 < 15%, growth, median CD4%, median viral load,
ART savings and ART-related adverse events. Children
were followed monthly for the first 3 months and then
every 3 months. CD4 by flow cytometry (BD Biosciences,
Becton Dickenson and Company, San Jose, CA, USA),
CBC, alanine transferase (ALT) were performed at every
visit, and viral load (Roche Amplicor Ultrasensitive assay,
Palo Alto, USA), and fasting lipids, glucose were per-
formed every 24 weeks. The tests were performed on-site,
both laboratories participated in the National Quality
Assurance Program. The study ended when the last child
reached week 108 of follow up. Adverse events were
graded according to 1994 Adult and Pediatric Grading
Tables of the Division of AIDS, National Institutes of
Health, Bethesda, MD.
Intention-to-treat analysis (ITT) with last value carried for-
wards was performed for all endpoint comparisons
between arms. On-treatment analysis (OT) was used to
evaluate ART response. Data were censored at the last fol-
low up visit for children who withdrew or were lost to fol-
low up. Growth was assessed by WAZ and HAZ using Thai
growth curves. Mann-Whitney test and Kruskal Willis test
were used to compare continuous variables between these
two and three groups. Chi-square and Fisher's exact test
were used to test proportion differences. Chi-square test
for trend was applied to identify whether there was a lin-
ear trend in the ordered proportion. In addition, we used
McNemar test to test proportion differences in the same
group.
The data management and analysis were conducted using
SPSS for Windows, version 12 (SPSS Inc., Chicago, IL).
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